Yishen Gushu formula exerts osteoprotective effects in OVX-Induced PMOP rats: role of ferroptosis Inhibition and iron metabolism correction
Jin B., Zeng H., Wei Z., Li Y., Zhang X.
Animal Study, published in Hereditas (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Hereditas (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41639935
- PMCID
- PMC12924249
- DOI
- 10.1186/s41065-026-00642-5
Abstract (original English)
BACKGROUND: Postmenopausal osteoporosis (PMOP) is a common bone disease among middle-aged and elderly women. Ferroptosis, a form of programmed cell death, plays a crucial role in the regulation of bone metabolism. Yishen Gushu Formula (YSGSF), a traditional Chinese medicine (TCM) compound, has clinical potential for treating PMOP, yet its specific mechanism of action remains unclear. OBJECTIVE: This study aims to investigate the specific mechanism by which YSGSF treats PMOP by inhibiting ferroptosis through mediating the NCOA4/GPX4 pathway. METHODS: The rat PMOP model was established by OVX and treated with YSGSF for 12 consecutive weeks. HE staining and micro-CT were used to examine bone tissue morphology and structure. Serum levels of E2, PINP, and β-CTX were measured by ELISA. RNA-seq analysis was performed to explore the potential mechanism of YSGSF. Oxidative stress markers (ROS, MDA, SOD, GSH, FE) in rat serum were determined. The regulatory effects of YSGSF on NCOA4, FTH1, GPX4, and SLC7A11 were evaluated by IHC and qRT-PCR. Erastin was used in vitro to induce ferroptosis in ROS17/28 osteoblasts, with cell viability and ferroptosis-related protein levels detected by CCK8 and Western blotting. RESULTS: YSGSF improved bone metabolism in OVX rats, alleviated osteoporotic morphological changes, promoted the overall structural recovery of trabecular bone, and increased bone d
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.